Compare Incyte Corporation (INCY) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Energy Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $113.17 (market cap $22.85B), while Energy Select Sector SPDR Fund trades at $65.16 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is the larger of the two by market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| INCY | XLE | |
|---|---|---|
Market Cap | $22.85B | $40.84B |
Volume | 1,927,029 | 50,409,268 |
Sector | Health | — |
52-Week High | $129.93 | $65.93 |
52-Week Low | $83.80 | $42.61 |
Typical Hold Time | 33 Days | 67 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
XLE trades at $65.27, up 2.98% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI at 70.16. The ETF, heavily concentrated in oil and gas, benefits from rising oil prices above $100 amid Middle East tensions and supply constraints. Recent news highlights strategic oil reserve releases and diesel price pressures, influencing energy sector volatility.
Outlook remains tied to oil price dynamics, with upside from sustained geopolitical risks but downside if crude reverses. Risks include oil market volatility and potential Fed rate hikes. Analyst sentiment is mixed, balancing energy sector strength against overbought technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
